DealBio
All collections

Investor Intelligence

11 Seed Investors Funding European Biotech

Seed investors with recent activity across therapeutics, drug discovery, RNA, immunology and platform biotechnology in Europe.

Published
  • Biotech
  • Seed
  • Therapeutics
  • Drug Discovery
  • Europe

European biotech seed rounds are drawing capital from specialist life-science funds, science-focused venture builders, regional investors and translational organisations. The common thread is willingness to fund technical risk before clinical validation, whether the starting point is a new therapeutic mechanism, a biological platform or a research-led spinout.

DealBio selected eleven investors to feature based on demonstrated seed-stage biotech activity across Europe. The list is not a ranking.

Oxford Science Enterprises

Science-focused investor and venture builder creating and backing companies from the University of Oxford ecosystem.

Stage
Pre-Seed · Seed · Series A
Sector / Focus
Life Sciences · Drug Discovery · Deep Science
Investment markets
United Kingdom
Investor type
VC / Venture Builder

Relevant investment

Oxford Science Enterprises co-led Scripta Therapeutics’ $12 million seed round in November 2025 with Apollo Health Ventures. Scripta combines AI, imaging and patient-derived models to map disease-driving transcriptional networks and discover disease-modifying drugs that alter activity.

AdBio Partners

European life-sciences VC focused on company creation and early-stage biotechnology.

Stage
Pre-Seed · Seed · Series A
Sector / Focus
Biotech · Therapeutics · Company Creation
Investment markets
France · Europe
Investor type
VC / Company Builder

Relevant investment

AdBio Partners co-led EvlaBio’s €21 million seed round in July 2025. EvlaBio is developing a first-in-class against the FGF23/FGFR4 signalling pathway to treat left-ventricular hypertrophy associated with chronic kidney disease, with the financing intended to complete preclinical development and advance toward .

BioGeneration Ventures

Dutch early-stage investor focused on European biotech, medtech and diagnostics.

Stage
Seed · Series A
Sector / Focus
Biotech · Therapeutics · Life Sciences
Investment markets
The Netherlands · Europe
Investor type
VC

Relevant investment

BioGeneration Ventures participated in Avidicure’s $50 million seed financing in April 2025. Amsterdam-based Avidicure is developing a new class of multifunctional, antibodies designed to deliver targeted immune stimulation in cancer while limiting activity in healthy tissue.

V-Bio Ventures

Belgian life-sciences VC investing in and co-creating early-stage science-driven startups.

Stage
Seed · Series A
Sector / Focus
Biotech · Therapeutics · Life Sciences
Investment markets
Belgium · The Netherlands · Europe
Investor type
VC

Relevant investment

V-Bio Ventures also participated in Avidicure’s $50 million seed round in 2025. Avidicure’s AVC-Booster platform uses dual agonistic antibodies to concentrate immune activation around tumour targets, giving V-Bio exposure to a differentiated antibody modality at company-launch stage.

Qbic Fund

Belgian seed and early-stage fund focused on university spinouts and research-based startups.

Stage
Pre-Seed · Seed
Sector / Focus
Biotech · University Spinouts · Deep Tech
Investment markets
Belgium · Europe
Investor type
VC

Relevant investment

Qbic participated in Spica Therapeutics’ €10 million seed round in June 2025. Spica is developing therapies that target defined , with its lead programme centred on an anti-CD163 monoclonal antibody intended to move into IND-enabling development.

Curie Capital

Amsterdam-based life-sciences VC investing in seed and Series A biotechnology, therapeutics, diagnostics and medtech.

Stage
Seed · Series A
Sector / Focus
Biotech · Therapeutics · Life Sciences
Investment markets
The Netherlands · Europe
Investor type
VC

Relevant investment

Curie Capital co-led Laigo Bio’s €11.5 million seed financing in December 2025. Laigo is developing SureTACs, a platform designed to remove disease-relevant membrane proteins, initially across oncology, autoimmune disease and graft rejection.

Biovance Capital

Portuguese biotech-focused VC investing in early-stage life-science startups across Europe.

Stage
Seed · Series A
Sector / Focus
Biotech · Therapeutics · Life Sciences
Investment markets
Portugal · Europe
Investor type
VC

Relevant investment

Biovance Capital invested €4 million in Laigo Bio in March 2026 and co-led the second close that brought Laigo’s total seed financing to €17 million. The capital is being used to advance SureTAC oncology programmes toward the clinic and develop immunology candidates.

Cancer Research Horizons

Cancer Research UK’s innovation arm, investing in and building early-stage oncology ventures.

Stage
Pre-Seed · Seed
Sector / Focus
Oncology · Therapeutics · Translational Science
Investment markets
United Kingdom · Europe
Investor type
Translational Investor

Relevant investment

Cancer Research Horizons invested in Infinitopes’ £12.8 million seed round in 2024 and continued participating when the round expanded to $35.1 million in January 2026. Oxford-based Infinitopes combines discovery, AI and vaccine-vector technology to develop off-the-shelf , with its lead programme moving into first-in-human testing.

ROM Utrecht Region

Regional development investor providing capital to innovative startups in the Utrecht ecosystem.

Stage
Seed
Sector / Focus
Life Sciences · Health · Regional Innovation
Investment markets
The Netherlands
Investor type
Public / Regional Investor

Relevant investment

ROM Utrecht Region participated in Laigo Bio’s €11.5 million seed round in December 2025. Laigo’s technology originated from research at UMC Utrecht and Oncode Institute, making the investment a direct example of regional capital supporting local academic science through company formation and early therapeutic development.

4BIO Capital

Specialist life-sciences VC focused on advanced therapies and emerging therapeutic modalities.

Stage
Seed · Series A
Sector / Focus
· Cell & Gene Therapy · Advanced Therapies
Investment markets
United Kingdom · Europe
Investor type
VC

Relevant investment

4BIO Capital first invested in Swiss biotech Araris Biotech at seed stage and later led its Series A. In March 2025, Araris agreed to be acquired by Taiho Pharmaceutical for $400 million upfront and up to $1.14 billion including milestones, providing a clear example of 4BIO backing an advanced-therapy platform from seed through exit.

Advent Life Sciences

Transatlantic life-sciences investor that starts and backs early- and mid-stage biotech, medtech and drug-discovery startups.

Stage
Seed · Series A
Sector / Focus
Biotech · Drug Discovery · New Modalities
Investment markets
United Kingdom · Europe
Investor type
VC

Relevant investment

Advent Life Sciences is an investor in Epitopea, which closed a $14 million seed round in 2022 and a $31 million pre-Series A in 2024. Cambridge- and Montreal-based Epitopea identifies tumour-specific antigens hidden in cancer-associated genomic regions and uses them to develop off-the-shelf RNA immunotherapies and other cancer-treatment modalities.

Methodology

DealBio builds investor lists using structured investor research, demonstrated investment activity and current public verification where needed. The methodology highlights investors with evidenced relevance to the article’s sector, stage and geography.

Get the DealBio Pulse

Weekly insights on health and longevity startups, standout founders, key markets, and notable exits.

You can unsubscribe at any time.